Hinge Health (NYSE:HNGE) Price Target Raised to $115.00

Posted by Francis Steltz on Oct 3rd, 2026

Hinge Health (NYSE:HNGE – Free Report) had its price objective raised by Needham & Company LLC from $97.00 to $115.00 in a report released on Wednesday morning,Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.

A number of other research analysts also recently commented on the company. Zacks Research downgraded Hinge Health from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 11th. Wall Street Zen cut Hinge Health from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Bank of America initiated coverage on Hinge Health in a report on Tuesday. They issued a “buy” rating and a $110.00 price target for the company. Truist Financial increased their price target on shares of Hinge Health from $85.00 to $112.00 and gave the company a “buy” rating in a research note on Monday, August 10th. Finally, Piper Sandler reissued an “overweight” rating on shares of Hinge Health in a report on Wednesday, June 10th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $105.33.

Check Out Our Latest Stock Analysis on HNGE

Hinge Health Trading Down 0.3%

Shares of HNGE stock opened at $97.60 on Wednesday. The firm has a fifty day moving average price of $88.84 and a 200 day moving average price of $69.28. The company has a market cap of $7.88 billion, a P/E ratio of 76.25 and a beta of 1.37. Hinge Health has a 12 month low of $30.08 and a 12 month high of $99.73.

Hinge Health (NYSE:HNGE – Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.31. The company had revenue of $212.82 million for the quarter. Hinge Health had a return on equity of 51.60% and a net margin of 15.15%.The firm’s quarterly revenue was up 53.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.59 earnings per share. On average, equities analysts forecast that Hinge Health will post 1.25 EPS for the current year.

Insider Buying and Selling at Hinge Health

In related news, CEO Daniel Perez sold 150,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $89.44, for a total transaction of $13,416,000.00. Following the transaction, the chief executive officer owned 35,470 shares in the company, valued at $3,172,436.80. This trade represents a 80.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James Budge sold 55,561 shares of the firm’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $89.45, for a total value of $4,969,931.45. Following the transaction, the chief financial officer owned 349,062 shares in the company, valued at $31,223,595.90. This represents a 13.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 1,198,932 shares of company stock valued at $108,122,542. 18.92% of the stock is owned by insiders.

Institutional Investors Weigh In On Hinge Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HNGE. BIT Capital GmbH grew its position in Hinge Health by 79.3% during the 4th quarter. BIT Capital GmbH now owns 3,316,101 shares of the company’s stock worth $154,033,000 after purchasing an additional 1,466,577 shares during the last quarter. 11.2 Capital Management LLC acquired a new position in Hinge Health in the second quarter valued at $204,566,531. Wellington Management Group LLP raised its holdings in shares of Hinge Health by 169.7% in the second quarter. Wellington Management Group LLP now owns 1,205,584 shares of the company’s stock valued at $100,063,000 after buying an additional 758,594 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in shares of Hinge Health by 225.7% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,163,187 shares of the company’s stock worth $44,852,000 after buying an additional 806,007 shares during the period. Finally, Alkeon Capital Management LLC boosted its stake in shares of Hinge Health by 110.4% during the fourth quarter. Alkeon Capital Management LLC now owns 791,104 shares of the company’s stock worth $36,747,000 after buying an additional 415,093 shares during the period.

Hinge Health Company Profile

(Get Free Report)

Hinge Health, Inc is a digital healthcare company focused on musculoskeletal (MSK) conditions, including back and joint pain. The company provides virtual care designed to help members manage pain, improve mobility and avoid or delay more invasive treatments.

Its platform combines a mobile application, motion-sensing technology, personalized exercise therapy, education and support from a care team that may include clinical specialists. Hinge Health offers programs for conditions such as chronic back pain, knee pain and other common MSK issues, with services generally provided through employers, health plans and other healthcare organizations.

Hinge Health was founded in 2015 and is headquartered in San Francisco, California.